United Therapeutics Corporation (UTHR) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of United Therapeutics Corporation stock $799, price $566, upside +41.3%, quality 74 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $166.16 – $608.49 · fair‑value band $446.85 – $1,163 · the $565.72 price screens below the $799.14 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.
Follow United Therapeutics in your weekly email
Every Wednesday you see whether United Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Show moreShow less
It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products.
Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine.
It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.
The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Stock analysis
United Therapeutics Corporation (UTHR) currently trades at $565.72, while our model-based Fair Value estimate is $799.14, implying the stock looks roughly 29% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $894.47 per share, and 14 of the 24 models we run sit above the $565.72 price.
Bear case: the Economic Profit group reads lowest at $298.51, and 10 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $446.85 (bear) to $1,163 (bull), the price of $565.72 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
United Therapeutics Corporation reported revenue of $3.2B in FY2025 versus $1.7B in FY2021, a compound +17.2%/yr. Reported net income was $1.3B in FY2025, compounding +29.4%/yr from FY2021.
Key figures
Market cap $25.9B Large · P/E ratio 21.4 · P/S ratio 8.13 · EPS (TTM) $26.49 · Net margin 38.6% · Return on equity 19.1% · Return on assets (EBIT) 16.3% · Operating margin 37.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 85 out of 100 (medium confidence).
What moves the price
The share trades about 7% below its 52-week high and 26% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 41%, UTHR screens cheaper than that median.
Fair Value models
Bear$446.85Fair Value $799.14Bull$1,163
Price $565.72 · Upside +41.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($22.50 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 5 officers or directors sold shares worth $775.7M and none bought.
SalePaul A MahonEVP & GENERAL COUNSEL25× since Nov 13, 2025: 218,300 shares, avg. $521.09$113.8MNov 5, 202610b5-1 plan
SaleMartine A RothblattChairperson & CEO, Director189× since Nov 6, 2025: 1,757,575 shares, avg. $537.87$945.4MNov 4, 202610b5-1 plan
SaleNilda MesaDirector3× since Dec 9, 2025: 673 shares, avg. $528.30$355,544Sep 14, 2026
SaleJan MalcolmDirector9× since Dec 11, 2025: 720 shares, avg. $518.62$373,410Jul 10, 202610b5-1 plan
SaleJames EdgemondCFO AND TREASURER33× since Nov 10, 2025: 377,267 shares, avg. $536.52$202.4MJun 22, 202610b5-1 plan
SaleChristopher PatuskyDirector3× since Dec 15, 2025: 4,910 shares, avg. $556.13$2.7MApr 24, 2026
SaleChristopher CauseyDirector5× since Jan 2, 2026: 4,320 shares, avg. $538.39$2.3MMar 30, 202610b5-1 plan
SaleTommy G ThompsonDirector3× since Dec 18, 2025: 4,910 shares, avg. $511.76$2.5MMar 26, 2026
SaleJudy D. OlianDirector4× since Feb 27, 2026: 800 shares, avg. $521.25$416,998Mar 23, 202610b5-1 plan
SaleRay KurzweilDirector4,910 shares at $489.02$2.4MMar 4, 2026
Plus 2 more entries from the last 12 months.
Plus 162 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+10.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.5%
Start year 2020 (pandemic). Over 10 years: +8.1% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+18.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.20.9% vs 8.2%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.40% → 48%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +5.7% a year for the price and +6.8% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Strong IP protection around inhaled treprostinil supports high margins and cash flow, yet the narrow focus on a few pulmonary hypertension indications limits broader sustained growth.
Main risk: Liquidia’s approved Yutrepia dry-powder inhaled treprostinil could capture share from the Tyvaso franchise, which accounts for over half of revenues, pressuring sales and margins.
Bull case: Pipeline expansion into larger indications such as idiopathic pulmonary fibrosis and new delivery formats could offset any share loss in the core pulmonary hypertension franchise by broadening the revenue base.
Bear case: If competing inhaled treprostinil products and generics erode the Tyvaso franchise without sufficient pipeline offsets, the company’s heavy concentration on a narrow set of products could lead to sustained revenue declines.
United Therapeutics just won a court ruling that its patent covers inhaled treprostinil for pulmonary hypertension linked to interstitial lung disease. This bolsters its defense in an established indication while the company seeks broader approval for idiopathic pulmonary fibrosis. Will the strengthened intellectual property position drive sustained growth more than any limits from its focused therapeutic portfolio hold it back?
Compare United Therapeutics Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 550 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+41.3% · Top 25%
Profitability
Return on equity (12 months)19.1% · Top 25%
Return on assets16.9% · Top 25%
Net margin (12 months)38.6% · Top 25%
Operating margin (12 months)37.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)4.1% · Below median
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)21.4× · Cheaper than median
P/B3.65× · Priciest 25%
P/S (12 months)8.13× · Priciest 25%
Price / free cash flow (fiscal year)24.9× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is United Therapeutics Corporation (UTHR) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $799.14 versus a price of $565.72, about +41% upside (undervalued).
What is the fair value of UTHR?
Our model-based fair value for United Therapeutics Corporation is $799.14 (as of Nov 6, 2026), built from audited fundamentals. The current price: $565.72.
What is the quality score of UTHR?
United Therapeutics Corporation has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for United Therapeutics Corporation (UTHR)?
Our model-based price target is the fair value of $799.14 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario $446.85, optimistic scenario $1,163. It is a calculation from audited fundamentals, not an analyst target.
What is the United Therapeutics Corporation stock forecast for 2026?
Our models put fair value at $799.14, about +41% upside versus a price of $565.72 (undervalued). Cautious scenario $446.85, optimistic scenario $1,163. The calculation is refreshed regularly with new filings.
What is the revenue of United Therapeutics Corporation (UTHR)?
United Therapeutics Corporation reported trailing-twelve-month revenue of about $3.2B (latest available figure, as of Nov 6, 2026).
What growth is priced into United Therapeutics Corporation (UTHR)?
For today's price to be fair in a discounted-cash-flow model, United Therapeutics Corporation would have to grow free cash flow by +8.2 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.5 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of UTHR use?
Our models discount United Therapeutics Corporation at 8.1 %: a base by market capitalisation (large), damped by beta 0.48, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For United Therapeutics Corporation that is +8.2 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has United Therapeutics Corporation (UTHR) delivered so far?
Over the past 5 years revenue at United Therapeutics Corporation grew +16.5 % a year. The price currently implies +8.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of United Therapeutics Corporation (UTHR) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into United Therapeutics Corporation (+8.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of United Therapeutics Corporation (UTHR)?
The free-cash-flow yield on the price is 4.02 %: that much free cash flow United Therapeutics Corporation produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of United Therapeutics Corporation (UTHR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For United Therapeutics Corporation it is $799.14 per share (as of Nov 6, 2026), against a price of $565.72. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is United Therapeutics Corporation stock overvalued or undervalued in 2026?
As of Nov 6, 2026, UTHR trades below its calculated fair value: price $565.72, fair value $799.14, a gap of about +41% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of UTHR?
No. The price is what the market pays today ($565.72); the fair value is what the company's own numbers justify ($799.14). For United Therapeutics Corporation the two are $233.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is United Therapeutics Corporation worth?
The market values United Therapeutics Corporation at about $25.9B (market capitalisation, as of Nov 6, 2026). Per share that is $565.72; our models calculate a fair value of $799.14 per share.
What do the bullish and bearish scenarios say about UTHR?
Our models span a range for United Therapeutics Corporation: cautious scenario $446.85, base $799.14, optimistic $1,163 per share (as of Nov 6, 2026, price $565.72). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of UTHR?
United Therapeutics Corporation trades at a price-to-earnings ratio of 21.4 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $799.14 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, FY2017, FY2021, FY2025 ex one-offs: 13.2. Other multiples: PEG 2.2, P/B 3.7, P/S 8.1, EV/EBITDA 17.1.
What is the PEG ratio of UTHR?
The PEG ratio of United Therapeutics Corporation is 2.22 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of United Therapeutics Corporation (UTHR)?
Balance-sheet figures for United Therapeutics Corporation (as of Nov 6, 2026): return on equity 19.1%, debt of 0.04 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is UTHR from its 52-week high?
United Therapeutics Corporation trades at $565.72, about 7% below its 52-week high of $608.49 and 26% above the low of $447.45 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $799.14 is for.
Which stocks are comparable to United Therapeutics Corporation?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is United Therapeutics Corporation stock attractive at the current price?
The data as of Nov 6, 2026: price $565.72, calculated fair value $799.14 (+41%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of UTHR calculated?
We run United Therapeutics Corporation through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $799.14, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. United Therapeutics Corporation currently trades 29% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of United Therapeutics Corporation (UTHR)?
The closing price on Nov 5, 2026 was $565.72. Our model-based fair value is $799.14, about +41% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with United Therapeutics Corporation right now?
The model range is unusually wide ($446.85 to $1,163). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (74/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of United Therapeutics Corporation (UTHR) come from?
Earnings per share at United Therapeutics Corporation grew +8.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.0 %, EBIT margin −0.9 %, tax rate +2.0 %, residual (interest, one-offs) −0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of United Therapeutics Corporation
How large is the market capitalisation of United Therapeutics Corporation (UTHR)?
The market capitalisation of United Therapeutics Corporation is $25.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of United Therapeutics Corporation (UTHR)?
The price-to-sales ratio of United Therapeutics Corporation is 8.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of United Therapeutics Corporation (UTHR)?
Earnings per share at United Therapeutics Corporation are $26.49 (price ÷ EPS = P/E 21.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of United Therapeutics Corporation (UTHR)?
The net margin of United Therapeutics Corporation is 38.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of United Therapeutics Corporation (UTHR)?
The return on equity (ROE) of United Therapeutics Corporation is 19.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of United Therapeutics Corporation (UTHR)?
On an EBIT basis the return on assets of United Therapeutics Corporation is 16.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of United Therapeutics Corporation (UTHR)?
The operating margin of United Therapeutics Corporation is 37.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at United Therapeutics Corporation (UTHR)?
Revenue at United Therapeutics Corporation is growing +4.1% versus a year earlier (3y avg +18.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at United Therapeutics Corporation (UTHR)?
Earnings per share at United Therapeutics Corporation are growing −20.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does United Therapeutics Corporation (UTHR) hold?
United Therapeutics Corporation holds more cash than debt, $1.6B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch United Therapeutics Corporation in the live analysis
One click puts United Therapeutics Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026